SGLT‐2i And Atrial Fibrillation In The Cardiovascular And Renal Outcome Trials

To determine if sodium‐glucose cotransporter‐2 inhibitor (SGLT‐2i) can attenuate the incidence of atrial fibrillation (AF) in a high‐risk population, researchers evaluated data from trials comparing SGLT‐2is vs placebo in high‐risk persons with or without diabetes (ie, cardiovascular and renal outcome trials) and that described the incidence of AF as a serious adverse event. The following trials were included: EMPA‐REG OUTCOME trial, CANVAS, CANVAS‐R, DECLARE‐TIMI 58 trial, CREDENCE, DAPA‐HF, VERTIS‐CV, and DAPA‐CKD. In this review, findings revealed the presence of a significantly lower risk of incident AF for patients receiving SGLT‐2is vs placebo. Although AF, reported as a serious adverse event, was shown to have a statistically significant lower incidence, more inquiry is required to assess its clinical significance.

​

Source